Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):349–357. doi: 10.1111/j.1365-2125.1986.tb05206.x

Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

A A Ajayi, N Hockings, J L Reid
PMCID: PMC1400941  PMID: 3011047

Abstract

The effect of age on the pharmacodynamic responses to converting enzyme inhibitors, enalapril and enalaprilat was investigated in nine young (22-30 years) and nine sex-matched elderly (65-73 years), healthy volunteers. The groups differed in baseline blood pressure, young 121/64 mmHg, elderly 142/75 mmHg (P less than 0.01), but not in sodium intake or body weight. Both enalapril and enalprilat produced significant falls in blood pressure in both groups but no increase in heart rate in the supine or erect posture. The blood pressure fall was significantly greater in the elderly on both treatments and in both erect and supine posture. The greater fall in blood pressure in the elderly was associated with a more prolonged inhibition of plasma angiotensin converting enzyme activity. The apparent age-related difference in response appears to be due to the difference in baseline blood pressures between the groups. Further study of the usefulness of chronic dosing with angiotensin converting enzyme inhibitors in hypertension in the elderly is indicated.

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajayi A. A., Campbell B. C., Howie C. A., Reid J. L. Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens. 1985 Feb;3(1):47–53. doi: 10.1097/00004872-198502000-00008. [DOI] [PubMed] [Google Scholar]
  2. Ajayi A. A., Campbell B. C., Meredith P. A., Kelman A. W., Reid J. L. The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol. 1985 Jul;20(1):17–25. doi: 10.1111/j.1365-2125.1985.tb02793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bravo E. L., Tarazi R. C. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979 Jan-Feb;1(1):39–46. doi: 10.1161/01.hyp.1.1.39. [DOI] [PubMed] [Google Scholar]
  4. Bühler F. R., Burkart F., Lütold B. E., Küng M., Marbet G., Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975 Oct 31;36(5):653–669. doi: 10.1016/0002-9149(75)90168-x. [DOI] [PubMed] [Google Scholar]
  5. Bühler F. R., Laragh J. H., Baer L., Vaughan E. D., Jr, Brunner H. R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972 Dec 14;287(24):1209–1214. doi: 10.1056/NEJM197212142872401. [DOI] [PubMed] [Google Scholar]
  6. Campbell B. C., Sturani A., Reid J. L. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci (Lond) 1985 Jan;68(1):49–56. doi: 10.1042/cs0680049. [DOI] [PubMed] [Google Scholar]
  7. Case D. B., Wallace J. M., Keim H. J., Weber M. A., Sealey J. E., Laragh J. H. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med. 1977 Mar 24;296(12):641–646. doi: 10.1056/NEJM197703242961201. [DOI] [PubMed] [Google Scholar]
  8. Chiknas S. G. A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem. 1979 Jul;25(7):1259–1262. [PubMed] [Google Scholar]
  9. Derkx F. H., Wenting G. J., Man in 't Veld A. J., Verhoeven R. P., Schalekamp M. A. Control of enzymatically inactive renin in man under various pathological conditions: implications for the interpretation of renin measurements in peripheral and renal venous plasma. Clin Sci Mol Med. 1978 May;54(5):529–538. doi: 10.1042/cs0540529. [DOI] [PubMed] [Google Scholar]
  10. Dzau V. J. Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc Pharmacol. 1984;6 (Suppl 2):S377–S382. [PubMed] [Google Scholar]
  11. Gavras H., Brunner H. R., Laragh J. H., Sealey J. E., Gavras I., Vukovich R. A. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med. 1974 Oct 17;291(16):817–821. doi: 10.1056/NEJM197410172911603. [DOI] [PubMed] [Google Scholar]
  12. Gavras H., Brunner H. R., Turini G. A., Kershaw G. R., Tifft C. P., Cuttelod S., Gavras I., Vukovich R. A., McKinstry D. N. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4;298(18):991–995. doi: 10.1056/NEJM197805042981803. [DOI] [PubMed] [Google Scholar]
  13. Greenblatt D. J., Sellers E. M., Shader R. I. Drug therapy: drug disposition in old age. N Engl J Med. 1982 May 6;306(18):1081–1088. doi: 10.1056/NEJM198205063061804. [DOI] [PubMed] [Google Scholar]
  14. Hockings N., Ajayi A. A., Reid J. L. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986 Apr;21(4):341–348. doi: 10.1111/j.1365-2125.1986.tb05205.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hodsman G. P., Isles C. G., Murray G. D., Usherwood T. P., Webb D. J., Robertson J. I. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):832–834. doi: 10.1136/bmj.286.6368.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hodsman G. P., Zabludowski J. R., Zoccali C., Fraser R., Morton J. J., Murray G. D., Robertson J. I. Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol. 1984 Mar;17(3):233–241. doi: 10.1111/j.1365-2125.1984.tb02337.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Irvine N. A., Shepherd A. M. Age and blood pressure determine vasodepressor response to sodium nitroprusside. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):816–821. doi: 10.1097/00005344-198409000-00012. [DOI] [PubMed] [Google Scholar]
  18. Kannel W. B., Gordan T. Evaluation of cardiovascular risk in the elderly: the Framingham study. Bull N Y Acad Med. 1978 Jun;54(6):573–591. [PMC free article] [PubMed] [Google Scholar]
  19. Kikta D. C., Fregly M. J. Effect of chronic treatment with captopril on reactivity of aortic smooth muscle from normotensive and renal hypertensive rats. J Hypertens. 1983 Oct;1(3):267–275. doi: 10.1097/00004872-198310000-00011. [DOI] [PubMed] [Google Scholar]
  20. Lijnen P., Fagard R., Groeseneken D., M'Buyamba J. R., Staessen J., Amery A. The hypotensive effect of captopril in hypertensive patients is age-related. Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):655–660. [PubMed] [Google Scholar]
  21. McKenzie J. K., Clements J. A. Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol Metab. 1974 Apr;38(4):622–627. doi: 10.1210/jcem-38-4-622. [DOI] [PubMed] [Google Scholar]
  22. Meade T. W., Imeson J. D., Gordon D., Peart W. S. The epidemiology of plasma renin. Clin Sci (Lond) 1983 Mar;64(3):273–280. doi: 10.1042/cs0640273. [DOI] [PubMed] [Google Scholar]
  23. Millar J. A., Derkx F. H., McLean K., Reid J. L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982 Sep;14(3):347–355. doi: 10.1111/j.1365-2125.1982.tb01990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Someya N., Morotomi Y., Kodama K., Kida O., Higa T., Kondo K., Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):840–843. doi: 10.1097/00005344-198409000-00016. [DOI] [PubMed] [Google Scholar]
  25. Stumpe K. O., Kolloch R., Vetter H., Gramann W., Krück F., Ressel C., Higuchi M. Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure. Am J Med. 1976 May 31;60(6):853–865. doi: 10.1016/0002-9343(76)90905-0. [DOI] [PubMed] [Google Scholar]
  26. Sturani A., Chiarini C., Degliesposti E., Santoro A., Zuccalà A., Zucchelli P. Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol. 1982 Dec;14(6):849–855. doi: 10.1111/j.1365-2125.1982.tb02048.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Turini G. A., Brunner H. R., Gribic M., Waeber B., Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979 Jun 9;1(8128):1213–1215. doi: 10.1016/s0140-6736(79)91897-x. [DOI] [PubMed] [Google Scholar]
  28. Vaughan E. D., Jr, Laragh J. H., Gavras I., Bühler F. R., Gavras H., Brunner H. R., Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973 Sep 20;32(4):523–532. doi: 10.1016/s0002-9149(73)80044-x. [DOI] [PubMed] [Google Scholar]
  29. Waeber B., Brunner H. R., Brunner D. B., Curtet A. L., Turini G. A., Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980 Mar-Apr;2(2):236–242. doi: 10.1161/01.hyp.2.2.236. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES